Skip to main
EBS
EBS logo

Emergent BioSolutions (EBS) Stock Forecast & Price Target

Emergent BioSolutions (EBS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Emergent BioSolutions Inc has recently secured multiple contract modification awards, highlighting its strong position in the biodefense and infectious disease control sectors. A notable contract modification of $30 million from the Biomedical Advanced Research and Development Authority (BARDA) reinforces the company's financial stability and growth potential. These developments underline the value of Emergent's diverse product portfolio, primarily driven by its commercial segment, which emphasizes the positive outlook for the company's stock.

Bears say

Emergent BioSolutions Inc faces several significant risks that contribute to a negative outlook on its stock, including the potential for accelerated erosion of the NARCAN franchise due to increasing generic competition, which is critical for revenue generation. Additionally, the company may struggle to secure crucial government contracts for its medical countermeasures (MCMs) segment, thereby limiting its revenue potential from this important area. Lastly, the company has recognized impairments of long-lived assets, totaling $27.2 million, which further highlights financial vulnerabilities that could adversely affect future performance.

Emergent BioSolutions (EBS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Emergent BioSolutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Emergent BioSolutions (EBS) Forecast

Analysts have given Emergent BioSolutions (EBS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Emergent BioSolutions (EBS) has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Emergent BioSolutions (EBS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.